UNION CITY, Calif., Nov. 3, 2008 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today that it will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at the New York Palace Hotel in New York City. Don M. Bailey, the Company's President and Chief Executive Officer, will discuss the Company's business strategy and historical financial performance at 3:15 p.m. Eastern Time.
Attendance at the conference is by invitation only. A live audio webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available after the live presentation, and can also be accessed at www.questcor.com.
About Questcor
Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two commercial products, H.P. Acthar(r) Gel ("Acthar") and Doral(r). Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. For more information, please visit www.questcor.com.